AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01087125 — intervention group
Intervention type: DRUG
Intervention: No Interventions
Description: No Interventions
Study NCT04230551 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PTSMA
Description: Alcohol Septal Ablation
Study NCT04230551 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PTSMA
Description: Alcohol Septal Ablation
Study NCT00686608 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: glucose
Description: 0.3mg/kg of glucose
Study NCT00686608 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: fructose
Description: fructose IV bolus
Study NCT00686608 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: saline
Description: IV saline
Study NCT00020787 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: G17DT Immunogen
Description: Dose: 500 micrograms in 0.2mL Route: Deep intramuscular Schedule: Days 8, 36, and 64; an additional dose at week 2, cycle 7 will be administered
Study NCT00020787 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: dose: 100 mg/m2 Route: i.v. infusion in 500 mL in 0.9% NaCl administered up to 3 hours Schedule: day 1, and then every 4 weeks.
Study NCT00725725 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Cognitive-behavioral therapy
Description: Participants underwent 5 weekly CBT session (sessions were 60-90 minutes in duration).
Study NCT03481725 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: SHAM peripheral nerve stimulation with a percutaneously inserted lead and wearable SHAM stimulator (SPR Therapeutics, Cleveland, Ohio)
Description: SHAM peripheral nerve stimulation with a percutaneously inserted lead and wearable stimulator (SPR Therapeutics, Cleveland, Ohio) that does not generate electric current for 14 days
Study NCT04026022 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl Transdermal System
Description: Patients will be treated perioperatively with a new pain management, that has been modified to integrate the 2017 ESA guidelines on prevention/treatment of postoperative delirium. Moreover patients will be administered a 12µg/h Fentanyl TTS in the ER or PACU. The ER TTS will only be administered if the patients still has mild to intense pain after initial intravenous (i.v.) treatment as well as reposition of the fractured hip. Further aspects of the modified management are: avoiding benzodiazepines, allowing oral fluids up to 2 hours before surgery, intraoperative monitoring of anaesthesia depth and at least 1,8 ltr crystalloid infusion per day.
Study NCT04026022 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo plaster in the ER or PACU
Study NCT00725725 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Org 25935
Description: 4 mg Org 25935 is given in tablet form, a single dose 2 hours prior to 3 CBT sessions. A total of 3 doses of trial medication is given over a 2-week period.
Study NCT00725725 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Org 25935
Description: 12 mg Org 25935 is given in tablet form, a single dose two hours prior to 3 CBT sessions. A total of 3 doses of trial medication is given over a two-week period.
Study NCT00020787 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorouracil
Description: Dose: 1000mg/m2/day Route: 24-hour continuous infusion in 0.9% NaCl over 5 days Schedule: Day 1 to Day 5 (5-day infusion) and then every 4 weeks
Study NCT00968604 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: BikDD Nanoparticle
Description: Starting dose 0.04 mg/kg once weekly by vein over 10 minutes.
Study NCT00345397 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Percutaneous endoscopic colostomy (PEC) tube
Description: PEC placement for antegrade enemas uses commercially available PEG tubes
Study NCT03920917 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cryoballoon Pulmonary Vein isolation
Description: 1. Pulmonary vein isolation will be performed using a cryoballoon catheter.~2. Esophageal temperature will be monitored to prevent esophageal injury.~3. A 28mm second or third cryoballoon catheter will be used.~4. Esophageal temperature will be monitored to prevent esophageal injury.~5. Cryoablation will be performed for 180 secs at -45°C or below on condition that the pulmonary vein is occluded with a cryoballoon.~6. CMAP (compound motor action potential) monitoring will be done to avoid phrenic nerve damage during the freezing of the right superior pulmonary vein.~7. The procedure and cryoablation times will be evaluated.~8. Rhythm follow-up will be performed after the procedure in accordance with the aforementioned study design.
Study NCT03920917 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Radiofrequency Pulmonary Vein isolation and Additional Right Atrial linear ablation
Description: 1. Pulmonary vein isolation will be performed using a radiofrequency catheter.~2. Additional cavo-tricuspid isthmus ablation will be performed with a radiofrequency catheter.~3. Additional superior vena cava-right atrial septal linear ablation will be performed with a radiofrequency catheter.~4. If any other trigger came from beyond pulmonary vein is detected after the administration of isoproterenol, additional local radiofrequency ablation will be followed.~5. Evaluated the procedure and radiofrequency ablation time.~6. Rhythm follow-up will be performed after the procedure in accordance with the aforementioned study design.
Study NCT00841581 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranibizumab
Description: Ranibizumab 0.5 mgs. (0.05 mls.) intravitreally for 6 months then as needed prn for 6 months.
Study NCT04450589 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: ALRV5XR
Description: ALRV5XR oral supplement. Dose/Route/Schedule: 1 capsule/oral twice daily. Take one capsule in the morning and one capsule in the evening. Take 30-60 minutes before food. If stomach upset occurs, subjects will be instructed to take the capsule at the beginning of a meal.~There should be no deviation from the daily nutriment regimen (although in the event a capsule or day is missed, subject should continue with regimen the following day.)
Study NCT04450589 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ALRV5XR Shampoo
Description: ALRV5XR Shampoo. Dose/Route/Schedule: 3-7 ml, topical, daily. The amount of shampoo used will vary by subject, based on length of hair. Short hair will use approximately 3ml of shampoo per wash and long hair as much as 7 ml. For short hair, an amount equivalent to a quarter in the palm of a hand, and for long hair a half-dollar size.~There should be no deviation from the daily nutriment regimen (although in the event a day is missed, subject should continue with regimen the following day
Study NCT04450589 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ALRV5XR Conditioner
Description: ALRV5XR Conditioner. Dose/Route/Schedule: 3-7 ml, topical, daily. The amount of conditioner used will vary by subject based on length of hair. Short hair will use approximately 3ml of conditioner per wash and long hair as much as 7 ml. For short hair, an amount equivalent to a quarter in the palm of a hand, and for long hair a half-dollar size.~There should be no deviation from the daily nutriment regimen (although in the event a day is missed, subject should continue with regimen the following day
Study NCT04450589 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ALRV5XR Hair Follicle Serum (Nutriment)
Description: ALRV5XR topical Hair Follicle serum (Nutriment), sealed in an airless pump dispensing bottle, metered at 0.2ml per depression. Dose/Route/Schedule: 1ml, topical, daily, applied at night.~Topical serum (referred to as the Nutriment) dosage is metered as 5 x depressions of plunger per day to cover areas of thinning scalp and adjacent scalp areas. Care should be taken to limit the Nutriment in hair. Each depression is metered at 0.2ml for a daily dose of 1.0 ml. Each container has 30ml of Nutriment. Nutriment will dry within a few minutes and any on the hair will also dry. The dried effect in the hair should not cause oiliness or dryness on scalp or hair. There should be no deviation from the daily nutriment regimen (although in the event a day is missed, subject should continue with regimen the following day.)
Study NCT04450589 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo oral supplement. Dose/Route/Schedule: 1 capsule/oral twice daily. Take one capsule in the morning and one capsule in the evening. Take 30-60 minutes before food. If stomach upset occurs, subjects will be instructed to take the capsule at the beginning of a meal.~There should be no deviation from the daily nutriment regimen (although in the event a capsule or day is missed, subject should continue with regimen the following day.)
Study NCT04450589 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Shampoo
Description: Placebo Shampoo. Dose/Route/Schedule: 3-7 ml, topical, daily. The amount of shampoo used will vary by subject, based on length of hair. Short hair will use approximately 3ml of shampoo per wash and long hair as much as 7 ml. For short hair, an amount equivalent to a quarter in the palm of a hand, and for long hair a half-dollar size.~There should be no deviation from the daily nutriment regimen (although in the event a day is missed, subject should continue with regimen the following day
Study NCT04450589 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Conditioner
Description: Placebo Conditioner. Dose/Route/Schedule: 3-7 ml, topical, daily. The amount of conditioner used will vary by subject based on length of hair. Short hair will use approximately 3ml of conditioner per wash and long hair as much as 7 ml. For short hair, an amount equivalent to a quarter in the palm of a hand, and for long hair a half-dollar size.~There should be no deviation from the daily nutriment regimen (although in the event a day is missed, subject should continue with regimen the following day
Study NCT04450589 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Hair Follicle Serum (Nutriment)
Description: Placebo topical Hair Follicle serum (Nutriment), sealed in an airless pump dispensing bottle, metered at 0.2ml per depression. Dose/Route/Schedule: 1ml, topical, daily, applied at night.~Topical serum (referred to as the Nutriment) dosage is metered as 5 x depressions of plunger per day to cover areas of thinning scalp and adjacent scalp areas. Care should be taken to limit the Nutriment in hair. Each depression is metered at 0.2ml for a daily dose of 1.0 ml. Each container has 30ml of Nutriment. Nutriment will dry within a few minutes and any on the hair will also dry. The dried effect in the hair should not cause oiliness or dryness on scalp or hair. There should be no deviation from the daily nutriment regimen (although in the event a day is missed, subject should continue with regimen the following day.)
Study NCT00952653 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desvenlafaxine Succinate Sustained Release
Description: 50 mg DVS SR tablet days 1-6, period 2 only.
Study NCT00952653 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: 4 mg midazolam (2 mL midazolam syrup) day 1, period 1 and day 6, period 2.
Study NCT01211626 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ANA773
Description: ANA773 Tosylate Capsule
Study NCT00725725 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo is given in tablet form, a single dose 2 hours prior to 3 CBT sessions. A total of 3 doses of trial medication is given over a 2-week period.
Study NCT03060148 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Medtronic neurostimulation system
Description: Dual leads for spinal cord stimulation will be performed at 90% of the motor threshold for 24 hours/day at 50 Hz and pulse width 0.2 ms
Study NCT00844727 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rofecoxib
Study NCT00844727 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo pills
Study NCT03354962 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Nivolumab + Ipilimumab
Description: Nivolumab + Ipilimumab alone (standard dosage regimen)
Study NCT03354962 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Combined treatment schema
Description: SBRT (recommended optimal dose) with Nivolumab + Ipilimumab (standard dosage regimen)
Study NCT04388527 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: COVID-19 Convalescent Plasma
Description: Participants will receive 2 units of convalescent plasma collected from ABO-compatible donors who have recovered from COVID-19.
Study NCT02528318 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Lucinactant for inhalation
Description: Lucinactant for inhalation refers to the active investigational agent, lucinactant, in combination with the investigational delivery device (drug-device combination product)
Study NCT02528318 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: nCPAP alone
Description: nCPAP therapy
Study NCT03966469 — intervention group
Intervention type: OTHER
Intervention: Preoperative support person present
Description: Participants who bring a support person to their preoperative appointment.
Study NCT03966469 — intervention group
Intervention type: OTHER
Intervention: Patient Present Only
Description: Patient presents to their preoperative appointment without a support person.
Study NCT02846467 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Informed consent trough a portable video media
Description: Information provided to patients using the mobile application (iURO app)
Study NCT02846467 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Written informed consent
Description: Information provided to patient trough the traditional informed consent (written IC) for transurethral resection of bladder or prostate.
Study NCT03428048 — intervention group
Intervention type: PROCEDURE
Intervention: Hybrid procedure
Description: Ablation of the posterior aspect of the heart, an area thought to be the origin of chaotic arrhythmias in persistent Afib patients.
Study NCT03428048 — intervention group
Intervention type: PROCEDURE
Intervention: Endocardial ablations
Description: ablations occurring inside the heart isolating the pulmonary veins - blocking energy from creating irregular or chaotic heart beats with use of a catheter
Study NCT03428048 — intervention group
Intervention type: PROCEDURE
Intervention: left atrial appendage occlusion
Description: A procedure to isolate the left atrial appendage of the heart. this anatomic body is the origin of clot formation which can lead to stroke. the clot formation as a result of Afib
Study NCT04048174 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Topical probiotic treatment with Lactococcus lactis W136
Description: Nasal and sinus irrigation with reconstituted live probiotic bacteria
Study NCT04048174 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Topical probiotic treatment with Lactococcus lactis W136
Description: Nasal and sinus irrigation with reconstituted live probiotic bacteria
Study NCT04048174 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Saline irrigation
Description: Nasal and sinus irrigation with saline solution
Study NCT04048174 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Saline irrigation
Description: Nasal and sinus irrigation with saline solution
Study NCT02400073 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AutoSet for Her
Description: 3 months nightly usage of the AutoSet for Her device
Study NCT00383019 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xalatan
Description: latanoprost 0.005%, one rop once daily in evening
Study NCT00383019 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xalacom
Description: latanoprost 0.005% adn timolol 0.5%, one drop, once daily
Study NCT05036239 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Eccentric biceps curls
Description: 10 x 5 repetitions of eccentric biceps curls, interspaced by 30 seconds of rest.
Study NCT01426321 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Imaging guided LV lead positioning
Description: LV lead positioning guided by echocardiography (mechanical strain evaluation by speckle tracking) in combination with cardiac CT. A viable segment with the latest mechanical activation is targeted, and an appropriate optimal cardiac vein segment is then chosen using the CT images.
Study NCT00051636 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zoledronic Acid
Description: Zoledronic acid 5 mg in 5 mL of sterile water intravenous infusion.
Study NCT00051636 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Risedronate
Description: Oral risedronate 30 mg capsules.
Study NCT00051636 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to Risedronate
Description: Oral placebo of risedronate capsules.
Study NCT00051636 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo to Zoledronic Acid
Description: 5 mL of sterile water one dose intravenous infusion.
Study NCT00051636 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Calcium and Vitamin D
Description: Calcium and vitamin D supplements were supplied.
Study NCT00051636 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Calcium and Vitamin D
Description: Calcium and vitamin D supplements were supplied.
Study NCT01453374 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VIVITROL 380mg
Description: 380 mg IM injection given once monthly
Study NCT03523013 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CPAP
Description: CPAP treatment with different pressure for OSA patients
Study NCT03523013 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CPAP
Description: CPAP treatment with different pressure for OSA patients
Study NCT03263871 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: PTM202
Description: PTM202 given twice daily for 30 days.
Study NCT03263871 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: micro-nutrient sprinkles
Description: Micro-nutrient sprinkles will be given twice daily for 30 days.
Study NCT03263871 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: micro-nutrient sprinkles
Description: Micro-nutrient sprinkles will be given twice daily for 30 days.
Study NCT01631370 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Renal denervation
Description: The patients are examined prior to and 6 months after renal denervation. On the day of examination the patients will have blood samples taken and the hyperinsulinemic euglycemic clamp and muscle and adipose tissue biopsies will be performed.
Study NCT01211626 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Matching Placebo Capsule
Study NCT02265237 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ombitasvir/paritaprevir/ritonavir
Description: tablets
Study NCT02265237 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ribavirin
Description: tablets
Study NCT03593668 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: 2-week dose adjustment period（0-2weeks）\[before meals\] 0-2d： - ;250mg，po; -. 3-4d： - ;250mg，po; 250mg，po. 5-6d： 250mg，po; 250mg，po; 250mg，po. 7-9d: 250mg，po; 500mg，po; 250mg，po. 10-11d: 250mg，po; 500mg，po; 500mg，po. 12-14d: 500mg，po; 500mg，po; 500mg，po.~10-week dose stabilization period（3-12weeks） Metformin Hydrochloride Tablet 500mg tid po.
Study NCT03593668 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Benaglutide
Description: 2-week dose adjustment period（0-2weeks） \[before meals\] 0-2d: -; 0.1mg，iH; -; 3-4d: -; 0.1mg，iH; 0.1mg，iH; 5-6d: 0.1mg，iH; 0.1mg，iH; 0.1mg，iH; 7-9d: 0.1mg，iH; 0.2mg，iH; 0.1mg，iH; 10-11d: 0.1mg，iH; 0.2mg，iH; 0.2mg，iH; 12-14d: 0.2mg，iH; 0.2mg，iH; 0.2mg，iH.~10-week dose stabilization period（3-12weeks） Benaglutide Injection 0.2mg，100ul，tid，iH
Study NCT04783753 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EDP-514
Description: Subjects will receive EDP-514 on Days 1 and 14
Study NCT04783753 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EDP-514
Description: Subjects will receive EDP-514 on Days 1 and 23
Study NCT04783753 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EDP-514
Description: Subjects will receive EDP-514 on Days 1 and 8
Study NCT04783753 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole
Description: Subjects will receive itraconazole QD for 14 days
Study NCT04783753 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carbamazepin
Description: Subjects will receive carbamazepine BID for 23 days
Study NCT04783753 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quinidine
Description: Subjects will receive quinidine BID for 8 days
Study NCT03445468 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IL-YANG Quadrivalent Influenza Vaccine
Description: A single 0.5mL dose administrated as an intramuscular injection.
Study NCT03445468 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: IL-YANG Flu Vaccine Pre-filled Syringe
Description: A single 0.5mL dose administrated as an intramuscular injection.
Study NCT02631798 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Food grade dye mucosal staining
Description: mucosal staining with food grade dye
Study NCT01682837 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Potassium chloride powder
Description: 1 sachet mixed with 250 ml water (providing 20 meq K) given at breakfast and again dinner, for a total of 40 meq K/day, for 4 weeks